CNS effects of a CCR5 inhibitor in HIV-infected subjects: A pharmacokinetic and cerebral metabolite study

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 1, 2012, Pages 206-212

  Garvey, Lucy ^a,b   Nelson, Mark ^c   Latch, Ngaire ^a   Erlwein, Otto W ^a   Allsop, Joanna M ^d   Mitchel, Ann ^b   Kaye, Steve ^a   Watson, Victoria ^e,f   Back, David ^e   Taylor Robinson, Simon D ^b   Winston, Alan ^a,b  

^a ST MARY S HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

CSF; Magnetic; Maraviroc; Resonance; Spectroscopy

Indexed keywords

EMTRICITABINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; N ACETYLASPARTIC ACID; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CYCLOHEXANE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; BASAL GANGLION; CEREBRAL METABOLITE RATIO; CEREBROSPINAL FLUID; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VIVO STUDY; MALE; METABOLITE; PARAMETERS; PHASE 1 CLINICAL TRIAL; PROTON NUCLEAR MAGNETIC RESONANCE; BRAIN; BRAIN LEVEL; CHEMISTRY; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PLASMA;

ADULT; ANTI-HIV AGENTS; BRAIN; BRAIN CHEMISTRY; CEREBROSPINAL FLUID; CYCLOHEXANES; FEMALE; HIV INFECTIONS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PLASMA; RECEPTORS, CCR5; TRIAZOLES;

EID: 84859206581     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr427     Document Type: Article

References (35)

1. Letendre S, Marquie-Beck J, Capparelli E et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65: 65-70.
2. WinstonA, GarveyL. Clinical implicationsof antiretroviral pharmacokinetics and pharmacodynamics in the CNS. HIV Ther 2009; 3: 361-7.
3. Anthonypillai C, Gibbs JE, Thomas SA. The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses.Cerebrospinal Fluid Res 2006; 3: 1.
4. Zhou XJ, Havlir DV, Richman DD et al. Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. AIDS 2000; 14: 2869-76.
5. Kravcik S, Gallicano K, Roth V et al. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir. J Acquir Immune Defic Syndr 1991; 21: 371-5.
6. Best BM, Letendre SL, Brigid E et al. Low atazanavir concentrations in cerebrospinal fluid. AIDS 2009; 23: 83-7.
7. Strazielle N, Ghersi-Egea JF. Factors affecting delivery of antiviral drugs to the brain. Rev Med Virol 2005; 15: 105-33.
8. Celsentri: Summary of Product's Characteristics. http://www.medicines.org.uk/emc/medicine/20386/SPC/Celsentri (30 August 2011, date last accessed).
9. Sierra-Madero J, Di Perri G, Wood R et al. Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study. HIV Clin Trials 2010; 11: 125-32.
10. Hardy WD, Gulick RM, Mayer H et al. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 2010; 55: 558-64.
11. Spudich SS, Huang W, Nilsson AC et al. HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. J Infect Dis 2005; 191: 890-8.
12. Yilmaz A, Watson V, Else L et al. Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients. AIDS 2009; 23: 2537-40.
13. Tiraboschi JM, Niubo J, Curto J et al. Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients. J Acquir Immune Defic Syndr 2010; 55: 606-9.
14. Melica G, Canestri A, Peytavin G et al. Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms. AIDS 2010; 24: 2130-3.
15. Chesney MA, Ickovics JR, Chambers DB et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000; 12: 255-66.
16. Winston A, Garvey L, Scotney E et al. Does acute hepatitis C infection affect the central nervous system in HIV-1 infected individuals? J Viral Hepat 2010; 17: 419-26.
17. Winston A, Duncombe C, Li PC et al. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis 2010; 50: 920-9.
18. Marcus CD, Taylor-Robinson SD, Sargentoni J et al. 1H MR spectroscopy of the brain in HIV-1-seropositive subjects: evidence for diffuse metabolic abnormalities. Metab Brain Dis 1998; 13: 123-36.
19. Naressi A, Couturier C, Devos JM et al. Java-based graphical user interface for the MRUI quantitation package. MAGMA 2001; 12:141-52.
20. Kanowski M, Kaufmann J, Braun J et al. Quantitation of simulated short echo time 1H human brain spectra by LCModel and AMARES.Magn Reson Med 2004; 51: 904-12.
21. Else L, Watson V, Tjia J et al. Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry(HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 1455-65. E
22. Roberts DJ, Goralski KB, Renton KWet al. Effect of acute inflammatory brain injury on accumulation of morphine and morphine 3- and 6-glucuronide in the human brain. Crit Care Med 2009; 37: 2767-74.
23. Kim SJ, Kim IJ, Kim YK et al. Probabilistic anatomic mapping of cerebral blood flow distribution of the middle cerebral artery. J NuclMed 2008; 49: 39-43.
24. Brooks WM, Friedman SD, Stidley CA. Reproducibility of 1H-MRS in vivo.Magn Reson Med 1999; 41: 193-7.
25. Paul RH, Yiannoutsos CT, Miller EN et al. Proton MRS and neuropsychological correlates in AIDS dementia complex: evidence of subcortical specificity. J Neuropsychiatry Clin Neurosci 2007; 19: 283-92.
26. Meyerhoff DJ, Bloomer C, Cardenas V et al. Elevated subcortical choline metabolites in cognitively and clinically asymptomatic HIV+patients. Neurology 1999; 52: 995-1003.
27. Lee PL, Yiannoutsos CT, Ernst T et al. A multi-center 1H MRS study of the AIDS dementia complex: validation and preliminary analysis. J Magn Reson Imaging 2003; 17: 625-33.
28. Haussinger D, Kircheis G, Fischer R et al. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? J Hepatol 2000; 32:1035-8.
29. Lang F, Busch GL, Ritter M et al. Functional significance of cell volume regulatory mechanisms. Physiol Rev 1998; 78: 247-306.
30. Burg MB. Molecular basis of osmotic regulation. Am J Physiol 1995;268: F983-96.
31. Solas C, Lafeuillade A, Halfon P et al. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47: 238-43.
32. Capparelli EV, Holland D, Okamoto C et al. Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS 2005; 19: 949-52.
33. DiCenzo R, DiFrancesco R, Cruttenden K et al. Lopinavir cerebrospinal fluid steady-state trough concentrations in HIV-infected adults. Ann Pharmacother 2009; 43: 1972-7.
34. Lafeuillade A, Solas C, Halfon P et al. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations. HIV Clin Trials 2002; 3: 27-35.
35. Abel S, Russell D, Taylor-Worth RJ et al. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008; 65 Suppl 1: 27-37.